SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 263 filers reported holding SAGE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,415,616 | -93.0% | 68,786 | -84.1% | 0.00% | -90.0% |
Q2 2023 | $20,294,302 | +131809.7% | 431,610 | +17.7% | 0.01% | +11.1% |
Q1 2023 | $15,385 | +370.8% | 366,663 | +327.9% | 0.01% | +350.0% |
Q4 2022 | $3,268 | -99.8% | 85,684 | +85.4% | 0.00% | +100.0% |
Q3 2022 | $1,809,000 | -28.9% | 46,205 | -41.4% | 0.00% | -50.0% |
Q2 2022 | $2,546,000 | -50.0% | 78,833 | -48.7% | 0.00% | -33.3% |
Q1 2022 | $5,087,000 | +347.0% | 153,686 | +474.5% | 0.00% | +200.0% |
Q4 2021 | $1,138,000 | -82.8% | 26,750 | -82.1% | 0.00% | -75.0% |
Q3 2021 | $6,627,000 | +66.7% | 149,568 | +113.7% | 0.00% | +100.0% |
Q2 2021 | $3,976,000 | +201.2% | 69,985 | +296.8% | 0.00% | +100.0% |
Q1 2021 | $1,320,000 | -18.5% | 17,637 | -5.8% | 0.00% | 0.0% |
Q4 2020 | $1,620,000 | -87.2% | 18,727 | -90.9% | 0.00% | -93.8% |
Q3 2020 | $12,637,000 | +0.9% | 206,751 | -31.4% | 0.02% | -5.9% |
Q2 2020 | $12,525,000 | -32.6% | 301,216 | -53.5% | 0.02% | -59.5% |
Q1 2020 | $18,595,000 | +127.7% | 647,470 | +472.3% | 0.04% | +281.8% |
Q4 2019 | $8,168,000 | +8.8% | 113,134 | +111.5% | 0.01% | -8.3% |
Q3 2019 | $7,504,000 | -75.8% | 53,497 | -83.5% | 0.01% | -75.0% |
Q4 2018 | $31,048,000 | -38.7% | 324,122 | -9.6% | 0.05% | -22.6% |
Q3 2018 | $50,666,000 | -14.8% | 358,699 | -5.6% | 0.06% | -20.5% |
Q2 2018 | $59,466,000 | +602.0% | 379,904 | +622.4% | 0.08% | +609.1% |
Q1 2018 | $8,471,000 | -32.2% | 52,592 | -30.7% | 0.01% | -38.9% |
Q4 2017 | $12,493,000 | +701.9% | 75,845 | +203.4% | 0.02% | +800.0% |
Q3 2017 | $1,558,000 | +313.3% | 25,000 | +371.0% | 0.00% | +100.0% |
Q1 2017 | $377,000 | -97.6% | 5,308 | -98.2% | 0.00% | -97.0% |
Q4 2016 | $15,483,000 | -53.5% | 303,227 | -58.0% | 0.03% | -41.1% |
Q3 2016 | $33,266,000 | +10.9% | 722,392 | -27.4% | 0.06% | -17.6% |
Q2 2016 | $29,995,000 | +69.0% | 995,536 | +79.9% | 0.07% | +54.5% |
Q1 2016 | $17,744,000 | -41.3% | 553,461 | +6.7% | 0.04% | -31.2% |
Q4 2015 | $30,242,000 | +4314.9% | 518,738 | +5429.7% | 0.06% | +6300.0% |
Q2 2015 | $685,000 | -90.8% | 9,381 | -93.6% | 0.00% | -92.9% |
Q1 2015 | $7,416,000 | +194.1% | 147,640 | +84.4% | 0.01% | +133.3% |
Q3 2014 | $2,522,000 | – | 80,078 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
RA Capital Management | 455,173 | $74,972,000 | 6.27% |
Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |